In addition, a case study reported a patient diagnosed with EML4-ALK V1-driven NSCLC who achieved a complete clinical response after being treated with chemotherapy plus RT, followed by crizotinib and alectinib [119]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.